| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC3168 | PF-562271 PHSO3H SALT Featured | PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively. |
|
| DC7059 | PF-03758309 Featured | PF-03758309 is an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. |
.gif)
|
| DC7081 | PF-04217903 Featured | PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant). |
|
| DC8353 | PF-04418948 Featured | PF-04418948 is an orally active, potent, and selective EP2 receptor antagonist (IC50 = 16 nM). |
|
| DC11367 | PF-04447943 Featured | PF-04447943 is a brain-permeable phosphodiesterase (PDE) inhibitor that is selective for PDE9A (IC50 = 12 nM) over other PDEs (IC50s = >940 nM) in enzymatic assays of second messenger hydrolysis. |
|
| DC7027 | Glasdegib(PF-04449913) Featured | PF-04449913 is a potent and orally bioavailable inhibitor of smoothened with IC50 of 5 nM(Gli-luciferase reporter reporter in C3H10T1/2); the hedgehog pathway inhibitor |
|
| DC7227 | PF-04620110 Featured | PF-04620110 is an orally active, selective and potent diglyceride acyltransferase-1 (DGAT1) inhibitor with IC50 of 19 nM. |
|
| DC3108 | PF-04971729 (Ertugliflozin) Featured | PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mellitus. |
|
| DC9915 | PF04995274,PF 04995274 Featured | PF-04995274 is a 5-HT4 receptor partial agonist. It thought to act centrally as a pro-cognitive agent that being developed for the treatment of Alzheimer's disease (AD). |
|
| DC10050 | PF05175157 Featured | PF-05175157 is a potent and selective inhibitor of both acetyl-CoA carboxylase isoform ACC1 located primarily in liver and adipose tissue and isoform ACC2 dominant in skeletal and heart muscle, with IC50 values of 27 nM and 33 nM, respectively. |
|
| DC11937 | PF 05180999 Featured | PF-05180999 (PF 5180999) is a potent, selective, brain-penetrating and orally bioavailable phosphodiesterase 2A (PDE2A) inhibitor with IC50 of 1 nM. |
|
| DC11734 | PF-06263276 | PF-06263276 (PF06263276, PF 6263276) is a potent, selective pan JAK inhibitor with IC50 of 2.2, 23.1, 59.9 and 29.7 nM for JAK1, JAK2, JAK3, and TYK2, respectively. |
|
| DC10631 | PF-06273340 | PF-06273340 is a highly potent, kinases elective, well-tolerated pan-Trk inhibitor with IC50 values of 6, 4, 3 nM for TrkA, TrkB, Trk C, respectively. |
|
| DC10500 | PF-06282999 Featured | PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases. |
|
| DC11466 | PF-06409577 Featured | PF-06409577 is a potent and selective allosteric activator of AMPK α1β1γ1 isoform with an EC50 of 7 nM. |
|
| DC11722 | PF-06459988 | PF-06459988 (PF06459988, PF 6459988) is a potent, selective, irreversible EGFR mutants with IC50 of 13, 7, 21 and 90 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively. |
|
| DC7924 | PF06463922(Lorlatinib) Featured | PF06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. |
|
| DC10779 | PF-06651600 Featured | PF-06651600 is a potent JAK3-selective inhibitor with an IC50 of 33.1 nM. |
|
| DC12488 | PF-06700841 tosylate Featured | PF-06700841 is an inhibitor of JAK1 and TYK2 kinases. PF-06700841 has been investigated for the treatment of psoriasis and lupus. |
|
| DC10022 | PF06840003 Featured | PF-06840003 is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1),with potential immunomodulating and antineoplastic activities. |
|
| DC2047 | Crizotinib (PF-2341066) Featured | PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley. |
|
| DC7201 | PF-2545920(MP-10) Featured | PF-2545920 a highly selective and potent PDE10A inhibitor with an IC50 of 0.37 nM. |
|
| DC1091 | PF-299804 (Dacomitinib,PF-00299804) Featured | PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively. |
|
| DC7480 | PF-3274167（cligosiban） Featured | PF-3274167 is a high-affinity nonpeptide oxytocin receptor (OTR) antagonist, with Ki of 9.5 nM. |
|
| DC3169 | PF-562271 Featured | PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively. |
|
| DC10451 | PFK158 Featured | PFK-158 is a potent and selective inhibitor of PFKFB3 that is currently being investigated in a phase I study in patients with advanced solid malignancies. |
|
| DC8335 | PQR-309(Bimiralisib) Featured | PI3K-IN-2 is a PI3K inhibitor, inhibits pPKB and pS6 with "++++/+++(+)" in A2058 melanoma cell. |
|
| DC10728 | Pibrentasvir(ABT-530) Featured | Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6. |
|
| DC10047 | PIM-447 dihydrochloride Featured | PIM447 is novel pan-PIM kinase inhibitor, including Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase. |
|
| DC9815 | Pimodivir(VX-787） Featured | Pimodivir(VX-787) is a novel inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. |
|
